News for Avanos Medical, Inc. (AVNS)

Fourth Quarter Sales: Approximately $180 million from continuing operations.Organic Sales Growth: 5% increase compared to the previous year.Adjusted Diluted Ea

Feb 26, 2025 / 02:00PM GMTOperator Good morning ladies and gentlemen. Welcome to the Avanos fourth quarter 2024 earnings call. (Operator Instructions) This call

Avanos Medical Inc. (NYSE:AVNS) Q4 2024 Earnings Conference Call February 26, 2025 9:00 AM ETCompany ParticipantsScott Galovan - Vice President of Strategy...

Florida-based Enveric Biosciences, Inc. (ENVB) is up over 155 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Avanos Medical (AVNS) delivered earnings and revenue surprises of 7.50% and 1.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PR NewswireALPHARETTA, Ga., Feb. 26, 2025 ALPHARETTA, Ga., Feb. 26, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter an

On February 26, 2025, Avanos Medical Inc (AVNS) released its 8-K filing, reporting its fourth quarter and full-year 2024 financial results. Avanos Medical Inc,

On December 31, 2024, T. Rowe Price Investment Management, Inc. (Trades, Portfolio) executed a notable transaction by acquiring an additional 644,267 shares of

Avanos Medical (AVNS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

AVNS' strong product line and focus on R&D raise optimism about the stock.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Revenue: Approximately $170 million from continuing operations.Adjusted Diluted Earnings Per Share: $0.36.Adjusted EBITDA: Approximately $31 million, or almost

Oct 30, 2024 / 01:00PM GMTOperator Good morning, ladies and gentlemen, and welcome to the Avanos Medical, Avanos third quarter 2024 earnings call. (Operator Ins

Avanos Medical Inc. (NYSE:AVNS) Q3 2024 Results Conference Call October 30, 2024 9:00 AM ETCompany Participants Scott Galovan - Vice President of Strategy...

Shares of Avanos Medical Inc (AVNS) fell 13.12% in mid-day trading on Oct 30. The stock reached an intraday low of $18.75, before recovering slightly to $19.6

Revenue: Reported at $170.4 million, falling short of the analyst estimate of $175.33 million, and representing a 0.5% decrease from the prior year.Net Income:

Avanos Medical (AVNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

The demand for automated cell culture is mainly driven by rising investments in cell-based research, advancements in cell culture technology, and an...

Discover the booming Enteral Feeding Devices Market, projected to grow from USD 4.1 billion in 2023 to USD 6.6 billion by 2031, fueled by a 6.1% CAGR....